Soleno Therapeutics Inc header image

Soleno Therapeutics Inc

SLNO

Equity

ISIN null / Valor 121339545

NASDAQ (2026-01-30)

USD 38.56-4.91%

Soleno Therapeutics Inc
UMushroom community rating:

4.14 8 votes No rating yet

NegativeNeutralPositive

About company

Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, which are designed as a once-daily oral treatment for Prader-Willi syndrome (PWS), a complex genetic disorder. Currently, DCCR is undergoing evaluation in a Phase 3 clinical development program. Soleno aims to address unmet medical needs by providing safe and effective therapeutic solutions that enhance the quality of life for patients with life-threatening rare conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-22.6%1Y

1,292%3Y

31.2%5Y

Performance

71.8%1Y

128%3Y

121%5Y

Volatility

2071 M

Market cap (USD)

3,272,771

Daily traded volume (Shares)

45.46 / 43.99

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.14

8 votes

Performance:

4.06

Innovation:

4.14

Society:

3.84

Nature:

3.86

Yiling Guo

United Kingdom, 09 Nov 2025

Good financial performance and under valued

Aditya Jain

United Kingdom, 09 Nov 2025

Good

Meruert Daniyarkyzy

United Kingdom, 09 Nov 2025

Volatile and high risk, but offers notable upside potential if its lead treatment succeeds.

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp

Edwards Lifesciences Corp Valor: 1065343

Annual Return

-50%0%+50%

Risk level

110

-0.16%USD 81.36

Galenica Ltd.

Galenica Ltd. Valor: 36067446

Annual Return

-50%0%+50%

Risk level

110

-0.36%CHF 96.60

Idorsia Ltd

Idorsia Ltd Valor: 36346343

Annual Return

-50%0%+50%

Risk level

110

1.11%CHF 3.65

Ypsomed Holding AG

Ypsomed Holding AG Valor: 1939699

Annual Return

-50%0%+50%

Risk level

110

-0.49%CHF 305.50

Medacta Group Ltd

Medacta Group Ltd Valor: 46852522

Annual Return

-50%0%+50%

Risk level

110

-2.59%CHF 165.20

CG Oncology Inc

CG Oncology Inc Valor: 131996952

Annual Return

-50%0%+50%

Risk level

110

-2.56%USD 52.05

AEVIS VICTORIA SA

AEVIS VICTORIA SA Valor: 47863410

Annual Return

-50%0%+50%

Risk level

110

-0.72%CHF 13.70

Biogaia AB

Biogaia AB Valor: 118922125

Annual Return

-50%0%+50%

Risk level

110

-1.08%SEK 109.60

Xvivo Perfusion AB

Xvivo Perfusion AB Valor: 19661174

Annual Return

-50%0%+50%

Risk level

110

-4.66%SEK 225.20

COSMO Pharmaceuticals N.V.

COSMO Pharmaceuticals N.V. Valor: 32590356

Annual Return

-50%0%+50%

Risk level

110

1.05%CHF 115.80

SIX

FactSet

Clearbit

Logos provided by Clearbit